As Court Battle Rages, Pfizer's Celebrex Sales Soar

Law360, New York (July 13, 2007, 12:00 AM EDT) -- In its annual financial statement to the U.S. Securities and Exchange Commission, drug maker Pfizer Inc. warned that “continuing concern” about the safety of its anti-inflammatory drug Celebrex might limit the company's ability to increase sales.

The concerns prompted the drug maker to embark on a direct-to-consumer TV ad campaign this April, which was “helping to stimulate patient interest,” the company told the SEC this week, and had contributed to total worldwide sales of $1.1 billion in the first half of 2007.

In Pfizer's statement to...
To view the full article, register now.